[A study on the clinical efficacy and safety of cefuzonam with long-term administration in chronic complicated urinary tract infections].
A new member of injectable cephem antibiotics, cefuzonam (L-105, CZON) was administered in the treatment of 11 chronic complicated urinary tract infections (CC-UTI) which were considered to be for indications of long-term chemotherapy. The results obtained are summarized as follows. Responses in 6 cases out of 9, 66.7%, were evaluated as excellent or moderate by the criteria of the Japan UTI committee at fifth day's judgement. At the end of the treatment, however, only 3 out of 8, 37.5% were determined to be effective. The apparent decrease in the efficacy of the drug after the longer treatment period was caused by replacements of susceptible bacteria with resistant strains. Side reactions were observed in 2 cases, one was diarrhea and the other was chill and fever. In these cases, the administration of the drug was discontinued, and the conditions returned to normal within a few days. In laboratory tests, a slight decrease of thrombocyte was observed in 1 case. The CZON was very effective against infections caused by susceptible bacteria. No differences between CZON and other related compounds were found with regard to safety, hence it was estimated that the drug was highly useful for a long-term treatment on infections caused by susceptible strains to CZON.
D000328:Adult; D000368:Aged; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; C049934:cefuzonam; D015296:Ceftizoxime